Hansa Biopharma AB (publ) (FRA:24H)
Germany · Delayed Price · Currency is EUR 2.972
-0.094 (-3.07%)
At close: Dec 1, 2025
Hansa Biopharma AB Employees
Hansa Biopharma AB had 135 employees as of December 31, 2024. The number of employees decreased by 33 or -19.64% compared to the previous year.
Employees
135
Change (1Y)
-33
Growth (1Y)
-19.64%
Revenue / Employee
€121,471
Profits / Employee
€436,026
Market Cap
307.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 135 | -33 | -19.64% |
| Dec 31, 2023 | 168 | 18 | 12.00% |
| Dec 31, 2022 | 150 | 19 | 14.50% |
| Dec 31, 2021 | 131 | 44 | 50.57% |
| Dec 31, 2020 | 87 | 13 | 17.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 318,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 103,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Hansa Biopharma AB News
- 19 days ago - Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript - Seeking Alpha
- 19 days ago - Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases - Slideshow - Seeking Alpha
- 4 weeks ago - Hansa Biopharma AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Hansa Biopharma AB (HNSBF) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue ... - GuruFocus
- 4 weeks ago - Q3 2025 Hansa Biopharma AB Earnings Call Transcript - GuruFocus
- 4 weeks ago - Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results - PRNewsWire
- 4 weeks ago - Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results - PRNewsWire